PPD Names VPs for North America and Asia

PPD Names VPs for North America and Asia

October 11, 2007

Expands global senior leadership team; restructures
business units geographically


    WILMINGTON, N.C., Oct. 11 /Xinhua-PRNewswire/ -- PPD,
Inc. (Nasdaq: PPDI) today announced the appointments of
Paul D. Colvin as senior vice president of clinical
operations for North America and Simon J. Britton as vice
president of clinical operations for Asia. 

    Mr. Colvin joins PPD from Eli Lilly and Company where
he most recently directed clinical operations and global
patient enrollment optimization. During his 14-year career
at Lilly, he held a series of leadership positions
including chief operations officer for the global
cardiovascular brand team; European clinical operations
senior manager for the oncology, critical care, primary
care and neuroscience business units; global clinical
operations manager for oncology project teams; and clinical
project management leader for the oncology project team.

    "Paul Colvin brings extensive global development
experience across a wide range of therapeutic areas
garnered during an impressive tenure with Lilly," said
William Sharbaugh, chief operating officer of PPD. "His
experience as a leader in the trenches of clinical drug
development will serve him well in overseeing our North
American Phase II-IV operational unit." 

    The position assumed by Mr. Britton is a new senior
management role created specifically for the company's
business on that continent.

    "With Asia's escalating importance to global drug
development, additional leadership will enable us to drive
PPD's continued growth in the region," Mr. Sharbaugh
said. "We are pleased to gain Simon Britton as a
member of our team with his comprehensive international
experience and proven ability to expand business scope and
deliver quality results."

    Mr. Britton spent the last seven years at
GlaxoSmithKline where he most recently served as head of
international clinical operations, managing the company's
global clinical operations group across 25 countries. He
brings more than 16 years' experience in leadership roles
in the biopharmaceutical industry.

    With Mr. Britton's appointment, PPD has divided its
Phase II-IV operational units into four distinct
territories: North America; Latin America; Europe, Middle
East and Africa (EMEA); and Asia. 

    "This strategic restructuring of our business
units geographically will enhance our ability to leverage
PPD talent globally, strengthen internal standardization of
our processes and further our ability to manage complex
multinational trials efficiently," Mr. Sharbaugh
added. 

    PPD is a leading global contract research organization
providing discovery, development and post-approval services
as well as compound partnering programs. Our clients and
partners include pharmaceutical, biotechnology, medical
device, academic and government organizations. With offices
in 29 countries and more than 10,000 professionals
worldwide, PPD applies innovative technologies, therapeutic
expertise and a commitment to quality to help its clients
and partners maximize returns on their R&D investments
and accelerate the delivery of safe and effective
therapeutics to patients. For more information, visit our
Web site at http://www.ppdi.com . 

    Except for historical information, all of the
statements, expectations and assumptions, including
expectations and assumptions about the above-named
employees' performance and value to PPD as well as the
geographic restructuring, contained in this news release
are forward-looking statements that involve a number of
risks and uncertainties. Although PPD attempts to be
accurate in making those forward-looking statements, it is
possible that future circumstances might differ from the
assumptions on which such statements are based. In
addition, other important factors which could cause results
to differ materially include the following: the ability to
attract and retain key personnel; competition within the
outsourcing industry; economic conditions and outsourcing
trends in the pharmaceutical, biotechnology and medical
device industries and government-sponsored research sector;
success in sales growth; loss of or delay in large
contracts; dependence on collaborative relationships; rapid
technological advances that make our products and services
less competitive; risks associated with acquisitions and
investments, such as impairments; and the other risk
factors set forth from time to time in the SEC filings for
PPD, copies of which are available free of charge upon
request from the PPD investor relations department. 


    For more information, please contact:

     Media:
     Louise Caudle
     Tel:   [phone]
     Email: [e-mail]

     Analysts/Investors:
     Steve Smith
     Tel:   [phone]
     Email: [e-mail]